This new infusion of capital comes only months after ArgoMed raised $3 million in a private equity round, and launched its Thermoflex System in the U.S.
The Thermoflex System is the first and only product in the U.S.
Carefully monitored clinical studies indicate that the Thermoflex System results in significant improvement of urinary flow rate.
The Thermoflex System is currently available in select East Coast cities and has been sold in Europe since mid-1998.
ArgoMed Inc., Research Triangle, N.C., an emerging developer and marketer of minimally invasive medical devices for the treatment of urological disorders, has introduced the Thermoflex System, an effective new treatment for benign prostatic hyperplasia (BPH).
"Argomed's new water-induced thermotherapy (WIT) procedure, administered by the Thermoflex System, is a simple, low-cost, pain-free therapy that requires no sedation.
The Thermoflex System circulates heated water, precisely controlled at 60 degrees C, through a proprietary catheter, thereby destroying obstructive prostatic tissue.
In addition, the Thermoflex system requires only topical anesthetic gel and can be performed in a physician's office, thereby eliminating risks associated with general anesthesia.